Last reviewed · How we verify
NCT06367673
Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia
Recruiting now
Phase 1
Last updated 18 April 2024
What this trial tests
Phase 1 trial testing iPSC-NK cells in AML, Adult in 24 participants. Currently enrolling.
Timeline
30 April 2024
Primary endpoint
31 March 2026
31 March 2026
31 August 2026
Quick facts
| Lead sponsor | Zhejiang University |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 30 April 2024 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 August 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- iPSC-NK cells — full drug profile →
Conditions studied
- AML, Adult — all drugs for AML, Adult →
Sponsor
Zhejiang University
Who can join
18 and older, any sex, with AML, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 or CD33 target Chimeric antigen receptor (CAR) -induced pluripotent stem cells derived NK cells in patients with relapsed/refractory AML
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.
Chen S, Zhu H, Jounaidi Y. · · 2024 · cited 106× · PMID 39511139 · DOI 10.1038/s41392-024-02005-w -
The clinical landscape of CAR NK cells.
Jørgensen LV, Christensen EB, Barnkob MB, Barington T. · · 2025 · cited 61× · PMID 40149002 · DOI 10.1186/s40164-025-00633-8 -
Unveiling the potential of CLL-1: a promising target for AML therapy.
Soleimani Samarkhazan H, Zehtabcheh S, Seraji HR, Beqaj SH, et al · · 2025 · cited 37× · PMID 39940055 · DOI 10.1186/s40364-025-00738-6 -
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.
Yao P, Liu YG, Huang G, Hao L, et al · · 2024 · cited 19× · PMID 39633491 · DOI 10.1186/s40164-024-00583-7 -
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.
Alidadi M, Barzgar H, Zaman M, Paevskaya OA, et al · · 2024 · cited 18× · PMID 39624236 · DOI 10.3389/fcell.2024.1491282 -
Comparative analysis of regulations and studies on stem cell therapies: focusing on induced pluripotent stem cell (iPSC)-based treatments.
Song SJ, Nam Y, Rim YA, Ju JH, et al · · 2024 · cited 18× · PMID 39574212 · DOI 10.1186/s13287-024-04065-9 -
CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy.
Dos Reis FD, Saidani Y, Martín-Rubio P, Sanz-Pamplona R, et al · · 2025 · cited 11× · PMID 40519903 · DOI 10.3389/fimmu.2025.1603757 -
A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?
Andrea AE, Chiron A, Sarrabayrouse G, Bessoles S, et al · · 2024 · cited 8× · PMID 39430751 · DOI 10.3389/fimmu.2024.1459818
Verify or expand the search:
- PubMed search for NCT06367673
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for AML, Adult
Currently open trials in the same condition.
- NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
- NCT07132684 — Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients · Phase 3 · recruiting
- NCT06533761 — Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML · Phase 1 · recruiting
- NCT07117422 — Venetoclax-Decitabine in Untreated Elderly/Unfit AML · NA · recruiting
- NCT06313437 — Revumenib in Combination With 7+3 + Midostaurin in AML · Phase 1 · recruiting
Other Zhejiang University trials
Trials by the same sponsor.
- NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
- NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
- NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
- NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT06367673 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
- Last refreshed: 18 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06367673.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing